HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance72% confidence

Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications

Source: FDA

Why This Matters

Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to AstraZeneca.

Regulatory Analysis

The purposes of eligibility criteria for cancer clinical trials are to select the intended patient population and reduce potential risks to trial subjects.

Supporting Context

Therapeutic area
Oncology · Combination Therapy
Sub-indication
General

Related signal: Phase Ib/II Trial of Olaparib with AZD2014 or AZD5363 in Recurrent Endometrial and Ovarian Cancer

Source

View source document

Related Signal

Open signal — Phase Ib/II Trial of Olaparib with AZD2014 or AZD5363 in Recurrent Endometrial and Ovarian Cancer
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.